CorMedix CRMD 深 沪
交易中 08-12 10:19:35 美东时间
10.9235
+0.854
+8.48%
华盛通- 最 高10.94
- 今 开10.35
- 成交量 77.67万股
- 最 低 10.30
- 昨 收 10.07
- 总市值 8.13亿
- 52周最高 17.43
- 市盈率 静 --
- 换手率 1.04%
- 52周最低 5.31
- 委 比 19.40%
- 总股本 7442.92万
- 历史最高 52.00
- 量 比 1.55
- 振 幅 6.36%
- 历史最低 0.73
- 每 手 1
- 风险率 2.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多21.55亿，这家抗生素企业被收购！
（来源：动脉新医药） 当地时间8月7日，生物制药公司CorMedix Inc. (NASDAQ:CRMD)和新型抗生素企业Melinta Therapeuti...
08-08 18:11
Somnigroup International's CorMedix to Acquire Melinta in $300M Deal, Expanding Infectious Disease Portfolio
CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC ("Melinta"),
08-07 19:14
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings
<p> CorMedix announced the acquisition of Melinta Therapeutics for $300 million, expanding its product portfolio with seven innovative hospital-focused infectious disease products and a pipeline with growth potential. The deal is expected to be accretive to EPS in 2026, with annual synergies of ~$35-$45 million. Pro forma 2025 revenues are estimated at $305-$335 million. The transaction advances CorMedix's strategy to build a specialty pharmaceu...
08-07 11:00
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
CorMedix Analyst Says Investors Could Be Further Rewarded
CorMedix boosts Q2 sales forecast as a major dialysis client accelerates DefenCath use, prompting positive analyst coverage and growth outlook.
07-01 02:24
D. Boral Capital Downgrades Cormedix to Hold
D. Boral Capital analyst Jason Kolbert downgrades Cormedix (NASDAQ:CRMD) from Buy to Hold.
06-30 22:44
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers NanoVibronix (NASDAQ:NAOV) shares increased by 45.2% to $1.25 during T...
06-27 05:05
CorMedix Inc. Announces Proposed Public Offering of Common Stock
CorMedix Inc. announced its intent to offer $85 million of its common stock in a public offering, with an option for underwriters to purchase an additional 15% of shares. Proceeds will be used for general corporate purposes, including R&D and potential strategic transactions. The offering is subject to market conditions and is being conducted under a Form S-3 shelf registration.
06-26 20:01
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
美股牛股 | Cidara治疗飙升逾110%，研发新药临床试验表现良好；SPTN大涨超50%
Cidara治疗飙升逾110%，公司研发新药临床试验表现出色；SPTN获大额溢价收购，飙涨超50%>>
06-24 19:15
